Skip to ContentSkip to Navigation
Practical matters How to find us drs. A.T. (Tim) Otten


Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases

The Risk of Developing Long COVID in Patients with Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?

Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD

Serological biomarkers of type I, III, and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease

The effect of riboflavin supplementation on the systemic redox status in healthy volunteers: A post-hoc analysis of the RIBOGUT trial

Use of Tumor Necrosis Factor-α Antagonists is Associated with Attenuated IgG Antibody Response against SARS-CoV-2 in Vaccinated Patients with Inflammatory Bowel Disease

Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease

Use of TNF-α-antagonists and systemic steroids is associated with attenuated imunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease

Vitamin C Supplementation in Healthy Individuals Leads to Shifts of Bacterial Populations in the Gut - A Pilot Study

Review: Local Tumor Necrosis Factor-alpha Inhibition in Inflammatory Bowel Disease

Read more